Zacks Small-Cap Research Issues An $11 Price Target On Protalix BioTherapeutics
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_03312022_PLX_Vandermosten.pdf
Recap: Protalix BioTherapeutics Q4 Earnings
Protalix BioTherapeutics (AMEX:PLX) reported its Q4 earnings results on Thursday, March 31, 2022 at 06:50 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell
• Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Protalix Bio, Chiesi Release Final Results From Late-Stage PRX-102 Trial In Fabry Disease
Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A, have
Protalix BioTherepeutics, Chiesi Global Rare Diseases Report Results Of BRIGHT Phase 3 Trial For Fabry Disease Treatment: ‘Study achieved key objectives for safety, efficacy and pharmacokinetics’
Study achieved key objectives for safety, efficacy and pharmacokinetics
After completion of the study, all patients enrolled in an extension study
Treatment with PRX-102 provided coverage for the entire four‑week period
Protalix BioTherapeutics Issues 2021 Letter To Stockholders
Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
Protalix BioTherapeutics Q3 EPS $(0.09) Up From $(0.14) YoY, Sales $12.05M Up From $10.79M YoY
Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.09) per share. This is a 35.71 percent increase over losses of $(0.14) per share from the same period last year. The company reported $12.05 million